Abstract 54P
Background
Treatment of human papilloma virus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) is still challenging, regarding its radio resistance and sparing of healthy surrounding tissue when applying radiotherapy (RT). Small molecules kinase inhibitors (smKI), targeting components of the DNA damage repair (DDR) pathway such as ATM and ATR, in combination with RT are promising to overcome these challenges. We hypothesized that inhibition von ATM vs. ATR concomitant to RT increases cellular toxicity and leads to diverse immune surface marker expression on HNSCC cells.
Methods
The effect of smKIs AZD0156 (ATMi) and VE-822 (ATRi) in combination with RT on HPV-pos. and HPV-neg. human HNSCC was analyzed. Colony formation (Co, smKI, RT, smKI+RT), immunogenic and non-immunogenic cell death (necrosis, apoptosis) were measured using Annexin/PI staining (flow cytometry). Immune-stimulating (ICOS-L, OX40-L, TNFSFR9, CD70) and immune-suppressive (PD-L1, PD-L2, HVEM) surface-marker were measured after 48h of treatment of HNSCC cells (HSC4, Cal33, UM-SCC-47, UD-SCC-2).
Results
Colony forming was significantly inhibited by smKI+RT in cancer cells, while sparing toxicity in healthy fibroblasts. Effects were more prominent in HPV-pos. compared to HPV-neg. HNSCC cells. Furthermore, ATRi demonstrated stronger cellular toxicity by inducing cell death at 0.1 μM compared to 1 μM ATMi. In contrast, ATMi only in combination with RT led to significant increase of apoptosis. After treatment with ATRi, upregulation of immune-suppressive checkpoint molecules on the cell surfaces was observed predominantly, but less influence on immune-stimulatory surface marker was found. Of note, ATMi treatment w/o RT led to even increased expression of both suppressive and stimulatory immune checkpoint molecules.
Conclusions
Inhibition of ATR shows greater toxicity, but ATM inhibition has stronger influence on the expression of immune checkpoint molecules. Taken together, combined treatment has the potential to be a therapeutic option that could improve tumor control without increasing toxicity in HNSCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Strahlenklinik Erlangen.
Funding
Bundesministerium für Bildung und Forschung (GREWIS-alpha, 02NUK050E).
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
63P - Role of EGFR-targeted therapy in the treatment of advanced and metastatic cervical cancers
Presenter: Abhishek Krishna
Session: Cocktail & Poster Display session
Resources:
Abstract
64P - Isothermal chemical KRAS denaturation assay for monitoring stability and inhibitors interactions
Presenter: Randa Mahran
Session: Cocktail & Poster Display session
Resources:
Abstract
65P - Influence of efflux and uptake transporters on the pharmacokinetics of the SYK inhibitors entospletinib and lanraplenib
Presenter: Nancy Loos
Session: Cocktail & Poster Display session
Resources:
Abstract
66P - Targeting allosteric sites on PDK-1 and PLK-1 with bioactive compounds from <italic>Daucus carota</italic> as a potential therapy for triple-negative breast cancer
Presenter: Kayode Raheem
Session: Cocktail & Poster Display session
Resources:
Abstract
67P - Molecular testing and treatment of patients with advanced solid tumors harboring an NTRK gene fusion: Interim results of the REALTRK registry
Presenter: Corinne Vannier
Session: Cocktail & Poster Display session
Resources:
Abstract
68P - Investigating CDK4/6 palbociclib resistance mechanisms in MCF7 breast cancer cell line
Presenter: Heloise Beutier
Session: Cocktail & Poster Display session
Resources:
Abstract
69P - Osimertinib is selective against NSCLC cells and modulates the multidrug-resistant phenotype in patient-derived cell cultures and co-cultures of NSCLC cells and fibroblasts
Presenter: Sofija Jovanović Stojanov
Session: Cocktail & Poster Display session
Resources:
Abstract
71P - Molecular Tumor Board at the European Institute of Oncology: An early Italian precision oncology experience
Presenter: Edoardo Crimini
Session: Cocktail & Poster Display session
Resources:
Abstract
72P - MDM alterations in patients with advanced or metastatic cancers
Presenter: Iwona Lugowska
Session: Cocktail & Poster Display session
Resources:
Abstract
73P - Automated detection of typical and atypical mitotic figures for improving survival prediction in breast cancer
Presenter: Saima Ben Hadj
Session: Cocktail & Poster Display session
Resources:
Abstract